0.0038EUR-9.52%Mkt Cap: 319288 EURP/E: 0.00Last update: 2026-05-14
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic at…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.01
PEG—
P/B-0.00
P/S159.64
EV/EBITDA11.89
EV/Revenue5420.90
EPS (TTM)2.23
EPS (Forward)-0.47
Cash Flow & Leverage
FCF Yield-694.32%
FCF Margin-110843.75%
Operating CF-2.07M EUR
CapEx (TTM)—
Net Debt/EBITDA11.87
Net Debt10.82M EUR
Technical
SMA 500.0047 (-18.9%)
SMA 2000.0112 (-66.1%)
Beta-0.15
S&P 52W Chg24.23%
Avg Vol (30d)515.54K
Avg Vol (10d)510.01K
Technical Indicators
RSI (14)42.7
MACD-0.0002
MACD Signal-0.0003
MACD Hist.+0.0001
BB Upper0.0043 EUR
BB Middle0.0040 EUR
BB Lower0.0037 EUR
BB Width15.51%
ATR (14)0.0004 EUR
Vol Ratio (20d)0.32x
52W Range
0.00360% of range0.0840
52W High0.0840 EUR
52W Low0.0036 EUR
Profitability
Gross Margin-1333.33%
EBITDA Margin45600.00%
Profit Margin3966.67%
Oper. Margin45050.00%
ROE-1.08%
ROA2.09%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-1.02
Current Ratio0.17
Quick Ratio0.17
Book Value/Sh-2.4250 EUR
Cash/Share0.0010 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10000
Split DateSep 3, 2024
Ownership
Shares Out.88.69M
Float4.28M
Insiders9.67%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap319.29K EUR
Enterprise Value10.84M EUR
Revenue (TTM)2.00K EUR
Gross Profit-40.00K EUR
Net Income (TTM)119.00K EUR
Revenue/Share0.0000 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees11
Last Price0.0038 EUR
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003846632